Longitudinal changes in blood biomarkers and their ability to predict type 2 diabetes mellitus—The Tromsø study

• Published in: Endocrinology, Diabetes & Metabolism
• Main Authors: Giovanni Allaoui, Charlotta Rylander, Maria Averina, Tom Wilsgaard, Ole‐Martin Fuskevåg, Vivian Berg
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2022
• Subjects: biomarkers; blood test; health service; longitudinal survey; preventive; risk factors; Diseases of the endocrine glands. Clinical endocrinology; RC648-665; Tromsø
• Online Access: https://doi.org/10.1002/edm2.325; https://doaj.org/article/aa5b3dd0facc44ca81d3eec4103b6f77

Abstract Introduction Identification of individuals at high risk of developing type 2 diabetes mellitus (T2DM) is important for early prevention of the disease. Once T2DM is established, it is difficult to treat and is associated with cardiovascular complications and increased mortality. We aimed to describe pre‐ and post‐diagnostic changes in blood biomarker concentrations over 30 years in individuals with and without T2DM, and to determine the predictive potential of pre‐diagnostic blood biomarkers. Methods This nested case–control study included 234 participants in the Tromsø Study who gave blood samples at five time points between 1986 and 2016: 130 did not develop T2DM and were used as controls; 104 developed T2DM after the third time point and were included as cases. After stratifying by sex, we investigated changes in pre‐ and post‐diagnostic concentrations of lipids, thyroid hormones, HbA1c, glucose and gamma‐glutamyltransferase (GGT) using linear mixed models. We used logistic regression models and area under the receiver operating characteristic curve (AROC) to assess associations between blood biomarker concentrations and T2DM, as well as the predictive ability of blood biomarkers. Results Cases and controls experienced different longitudinal changes in lipids, free T3, HbA1c, glucose, and GGT. The combination of selected blood biomarker concentrations and basic clinical information displayed excellent (AROC 0.78–0.95) predictive ability at all pre‐diagnostic time points. A prediction model that included HDL (for women), HbA1c, GGT, and basic clinical information demonstrated the strongest discrimination 7 years before diagnosis (AROC 0.95 for women, 0.85 for men). Conclusion There were clear differences in blood biomarker concentrations between cases and controls throughout the study, and several blood biomarkers were associated with T2DM. Selected blood biomarkers (lipids, HbA1c, GGT) in combination with BMI, physical activity, elevated blood pressure, and family history of T2DM had excellent ...